Bacterial Resistance, Methicillin-Sensitive Staphylococcus Aureus Infection
Conditions
Keywords
cefazolin, antistaphylococcal penicillins, Methicillin-Sensitive Staphylococcus Aureus Infection, Bacterial Resistance
Brief summary
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.
Interventions
None listed
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
French hospitals which have collected their consumption and resistance data on the French national database named CONSORES (From 2019 to 2022)
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Association between the cefazolin/antistaphylococcal penicillins consumptions and the resistant bacteria emergence | Between the first january 2018 and the 31st december 2022 | The total consumption of antibiotics (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) will be correlate with the resistant bacteria emergence (only incidence for each bacterial strain) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Factors associated with the emergence of resistant bacteria | Between the first january 2018 and the 31st december 2022 | Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.), type of antibiotics and intensity of consumption expressed in number of defined daily doses (DDD). |
| Factors associated with the consumption of antibiotics | Between the first january 2018 and the 31st december 2022 | Factors associated with the emergence of resistant bacteria will be described by a Cox model: hospital size (number of beds), location in France, activities (intensive care, surgery, etc.) and type of bacterial strain indentified (resistant or not). |
| Evolution of resistance in French hospitals | Between the first january 2018 and the 31st december 2022 | For each year, bacterial resistance will be described, in France and in each hospital, in the form of a quantitative variable: number of resistant bacterial strains isolated for each year (number of resistant strains / total number of strains). |
| Evolution of antibiotics consumption in French hospitals | Between the first january 2018 and the 31st december 2022 | For each year, antibiotic consumption will be described, in France and in each hospital, in the form of a quantitative variable (expressed as number of Defined Daily Doses (DDD) per 1000 inhabitants per day) |
Countries
France
Outcome results
None listed